Related Experiment Video
Updated: Jun 13, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma
Nguyen Tran Quang Sang1,2, Nguyen Van Khanh1,3, Hoang Hai1
1Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
Cancers
|June 12, 2026
Summary
A new blood test using immune checkpoint proteins (ICPs) like sHVEM and sCD27 can identify distinct subtypes of osteosarcoma. This minimally invasive approach aids in preoperative risk stratification for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Osteosarcoma is the most common pediatric bone cancer with stagnant survival rates.
- There is a critical need for non-invasive biomarkers for preoperative risk stratification.
- The prognostic value of combined circulating immune checkpoint proteins (ICPs) and bone remodeling factors (BRFs) in osteosarcoma is not well understood.
Purpose of the Study:
- To investigate the prognostic value of a novel two-marker immune checkpoint protein signature (ICP2) comprising sHVEM and sCD27 in osteosarcoma.
- To explore the combined prognostic utility of the ICP2 signature with soluble osteopontin (sOPN).
- To assess the potential of this minimally invasive biomarker panel for preoperative risk stratification.
Main Methods:
- Prospective analysis of plasma samples from 47 osteosarcoma patients.
- Quantification of ICPs and BRFs using multiplex immunoassays.
- Development of a two-marker ICP signature (ICP2) using sHVEM and sCD27, with subtypes determined by consensus clustering.
- Integrative analysis with sOPN and survival assessment using Kaplan-Meier and Cox regression models.
Main Results:
- Two ICP2 subtypes were identified, with ICP2-type2 significantly associated with worse progression-free survival (PFS) and overall survival (OS).
- The ICP2 model demonstrated high discriminative performance (C-index 0.924 for PFS, 0.903 for OS), with acceptable discrimination after accounting for overfitting.
- Elevated sOPN showed a trend towards poorer survival, and its integration with ICP2 provided modest additional value for OS stratification.
Conclusions:
- The circulating sHVEM/sCD27 signature effectively defines prognostically distinct osteosarcoma subtypes.
- This minimally invasive biomarker model shows promise for preoperative risk stratification in osteosarcoma.
- Integration with sOPN suggests a potential link between immune regulation and bone remodeling, requiring further validation.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...